• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Pharmacology of Dostarlimab: A Review
  • VIEWS 1067
  • PDF 243

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v21i2.2

Year: 2022, Volume: 21, Issue: 2, Pages: 44-47

Review Article

Pharmacology of Dostarlimab: A Review

Arnab Roy​✉ 1 , Akash Chaurasiya 2

 

1 Department of Pharmacology, Gautam Institute of Pharmacy, Jaitpur, Nalanda, Saidbarhi, Bihar, 801307, India.
2 Department of Pharmaceutics, Gautam Institute of Pharmacy, Jaitpur, Nalanda, Saidbarhi, Bihar, 801307, India.

Corresponding author ✉ : [email protected]

 

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Dostarlimab is a humanised anti-PD-1 immunoglobulin (IgG4) monoclonal antibody (mAb). It has a high affinity for the PD-1 receptor and effectively inhibits interactions with PD-L1 and PD-L2 by blocking their binding to the PD-1 receptor. Programmed cell death 1 (PD-1) is an immunological checkpoint receptor that transmits inhibitory signals to limit local inflammatory responses and preserve self-tolerance. It is found on antigen-activated and fatigued T cells. When the PD-1 receptor binds to the tumor-expressed ligands PD-L1 and PD-L2, T-cell proliferation and cytokine production are suppressed.

Keywords: Dostarlimab, PD­1 immunoglobulin, T - cell proliferation

References

  1. Markham A. Dostarlimab: First Approval. Drugs. 2021;81(10):1213–1219. Available from: https://doi.org/10.1007/s40265-021-01539-5
  2. Seban RDD, Donnadieu A, Journo G, Bidard FC, Richard C, Rouzier R, et al. 18F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab. Diagnostics. 2021;11(8):1353. Available from: https://doi.org/10.3390/diagnostics11081353
  5. Andre T, Berton D, Curigliano G, Ellard S, Pérez JMT, Arkenau HT, et al. Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. Journal of Clinical Oncology. 2021;39(3_suppl):9.
  6. Subramanian J, Moreno V, Bosch-Barrera J, Pikiel J, Kristeleit R, Guo W, et al. 1399P Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC) Annals of Oncology. 2020;31(31):S886–S887. Available from: https://doi.org/10.1016/j.annonc.2020.08.1713
  7. Kasherman L, Ahrari S, Lheureux S. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncology. 2021;17(8):877–892. Available from: https://doi.org/10.2217/fon-2020-0655
  8. Murtaza A, Laken H, Correia JS, PM, Altobell LJ, Zhang JG, et al. Discovery of TSR-022, a novel, potent anti-TIM-3 therapeutic antibody. Eur J Cancer. 2016;69:32901–32902. Available from: https://doi.org/10.1016/S0959-8049(16)32903-3
  9. Lizardo DY, Kuang C, Hao S, Yu J, Huang Y, Zhang L. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2020;1874(2):188447–18844. Available from: https://doi.org/10.1016/j.bbcan.2020.188447
  10. Dulos J, Carven GJ, Boxtel SJV, Evers S, Driessen-Engels LJA, Hobo W, et al. PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer. Journal of Immunotherapy. 2012;35(2):169–178. Available from: https://doi.org/10.1097/cji.0b013e318247a4e7
  11. Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, et al. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Molecular Cancer. 2018;17(1):129–142. Available from: https://doi.org/10.1186/s12943-018-0864-3
  13. Zhang XT, Chen H, Shao W, Lin ZJ, Melhem M, Lu S. A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042) AAPS Open. 2021;7(1):8. Available from: https://doi.org/10.1186/s41120-021-00039-w
  14. Patnaik A, Weiss GJ, Rasco DW, Blaydorn L, Mirabella A, Beeram M, et al. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial. Cancer Chemotherapy and Pharmacology. 2022;89(1):93–103. Available from: https://doi.org/10.1007/s00280-021-04358-3
  15. Gettman L. New Drug Update: Dostarlimab, Loncastuximab Tesirine, and Aducanumab. The Senior Care Pharmacist. 2022;37(1):9–16. Available from: https://doi.org/10.4140/tcp.n.2022.9
  16. Ajith JS, Muthe T, Pooja L, Kartik R, Tejas R. Dostarlimab – A New Believe In Cancer Treatment. IOSR Journal Of Pharmacy And Biological Sciences . 2022;17(3):49–53. Available from: https://www.iosrjournals.org/iosr-jpbs/papers/Vol17-issue3/Ser-2/H1703024953.pdf
  17. Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer. Future Oncology. 2021;17(29):3781–3785. Available from: https://doi.org/10.2217/fon-2021-0598

Copyright

© 2022 Published by Krupanidhi Educational Trust. This is an open-access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/)

  • 27 September 2022

Year: 2022, Volume: 21, Issue: 2


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.